Bokf Trimmed Its Abbvie INC (ABBV) Stake by $6.68 Million

AbbVie Inc. (NYSE:ABBV) LogoInvestors sentiment is 0.83 in Q1 2019. Its the same as in 2018Q4. It has no change, as 73 investors sold ABBV shares while 627 reduced holdings. only 134 funds opened positions while 450 raised stakes. 962.74 million shares or 3.37% less from 996.27 million shares in 2018Q4 were reported. Pittenger & Anderson reported 0.06% stake. Hgk Asset stated it has 0.15% in AbbVie Inc. (NYSE:ABBV). Btc Management Inc invested in 0.69% or 53,621 shares. Granite Inv Prtn Ltd Llc, California-based fund reported 30,418 shares. Cape Cod Five Cents National Bank & Trust accumulated 26,209 shares. Inv House Ltd Co accumulated 84,277 shares. Evergreen Mgmt Ltd reported 0.07% stake. Cibc Asset holds 269,184 shares or 0.13% of its portfolio. Manufacturers Life Insur Communication The accumulated 1.51 million shares. Farmers Fincl Bank owns 9,031 shares. Shelter Mutual Insurance invested 1.75% in AbbVie Inc. (NYSE:ABBV). Grimes Company reported 44,215 shares stake. Ledyard Bank & Trust reported 26,906 shares or 0.29% of all its holdings. Leavell Investment Mgmt has invested 0.62% in AbbVie Inc. (NYSE:ABBV). Lodestar Invest Counsel Limited Liability Il has invested 0.2% in AbbVie Inc. (NYSE:ABBV).

Since June 26, 2019, it had 6 insider purchases, and 0 selling transactions for $6.65 million activity. AUSTIN ROXANNE S had bought 11,500 shares worth $776,250 on Wednesday, June 26. $2.05M worth of stock was bought by CHASE WILLIAM J on Wednesday, June 26.

Bokf decreased its stake in Abbvie Inc (ABBV) by 38.73% based on its latest 2019Q1 regulatory filing with the SEC. Bokf sold 83,454 shares as the company’s stock declined 2.49% while stock markets rallied. The institutional investor held 132,002 shares of the major pharmaceuticals company at the end of 2019Q1, valued at $10.64 million, down from 215,456 at the end of the previous reported quarter. Bokf who had been investing in Abbvie Inc for a number of months, seems to be less bullish one the $103.90B market cap company. The stock increased 0.16% or $0.11 during the last trading session, reaching $70.28. About 12.40 million shares traded or 40.97% up from the average. AbbVie Inc. (NYSE:ABBV) has declined 25.60% since July 14, 2018 and is downtrending. It has underperformed by 30.03% the S&P500.

Bokf, which manages about $4.18 billion US Long portfolio, upped its stake in Agilent Technologies Inc (NYSE:A) by 49,120 shares to 60,349 shares, valued at $4.85 million in 2019Q1, according to the filing. It also increased its holding in Sterling Construction Co Inc (NASDAQ:STRL) by 468,513 shares in the quarter, for a total of 538,513 shares, and has risen its stake in Maxim Integrated Prods Inc (NASDAQ:MXIM).

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on July, 26. They expect $2.21 earnings per share, up 10.50 % or $0.21 from last year’s $2 per share. ABBV’s profit will be $3.27B for 7.95 P/E if the $2.21 EPS becomes a reality. After $2.14 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 3.27 % EPS growth.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: which released: “If You Like AbbVie, You Should Be Buying Allergan – Seeking Alpha” on July 13, 2019, also with their article: “Top Analyst Upgrades and Downgrades: AbbVie, ADM, Conoco, FedEx, Fox, Kinder Morgan, Lennar, Micron, Slack, Virtu and More – 24/7 Wall St.” published on June 26, 2019, published: “AbbVie SWOT Analysis – Seeking Alpha” on June 21, 2019. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: and their article: “Is AbbVie a Buy? – Yahoo Finance” published on July 02, 2019 as well as‘s news article titled: “7 Stocks on Sale the Insiders Are Buying – Yahoo Finance” with publication date: July 01, 2019.

AbbVie Inc. (NYSE:ABBV) Ratings Coverage

Among 3 analysts covering AbbVie (NYSE:ABBV), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. AbbVie had 10 analyst reports since January 23, 2019 according to SRatingsIntel. The company was maintained on Thursday, February 21 by Piper Jaffray. On Monday, April 29 the stock rating was upgraded by BMO Capital Markets to “Market Perform”. The firm has “Hold” rating given on Wednesday, March 13 by Piper Jaffray. UBS reinitiated AbbVie Inc. (NYSE:ABBV) rating on Wednesday, January 23. UBS has “Neutral” rating and $91 target.

AbbVie Inc. (NYSE:ABBV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.